Vijay K Iyengar - Net Worth and Insider Trading
Vijay K Iyengar Net Worth
The estimated net worth of Vijay K Iyengar is at least $3 Million dollars as of 2023-05-31. Vijay K Iyengar is the EVP, GMAPPS of Incyte Corp and owns about 42,835 shares of Incyte Corp (INCY) stock worth over $3 Million. Details can be seen in Vijay K Iyengar's Latest Holdings Summary section.
Transaction Summary of Vijay K Iyengar
Vijay K Iyengar Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Vijay K Iyengar owns 1 companies in total, including Incyte Corp (INCY) .
Click here to see the complete history of Vijay K Iyengar’s form 4 insider trades.
Insider Ownership Summary of Vijay K Iyengar
|Ticker||Comapny||Transaction Date||Type of Owner|
|INCY||Incyte Corp||2016-05-09||EVP GPS & BD & & Licensing|
Vijay K Iyengar Latest Holdings Summary
Vijay K Iyengar currently owns a total of 1 stock. Vijay K Iyengar owns 42,835 shares of Incyte Corp (INCY) as of January 26, 2023, with a value of $3 Million.
Latest Holdings of Vijay K Iyengar
|Ticker||Comapny||Latest Transaction Date||Shares Owned||Current Price ($)||Current Value ($)|
Holding Weightings of Vijay K Iyengar
Vijay K Iyengar Form 4 Trading Tracker
According to the SEC Form 4 filings, Vijay K Iyengar has made a total of 10 transactions in Incyte Corp (INCY) over the past 5 years, including 0 buys and 10 sells. The most-recent trade in Incyte Corp is the sale of 7,000 shares on January 26, 2023, which brought Vijay K Iyengar around $595,000.
Insider Trading History of Vijay K Iyengar
Vijay K Iyengar Trading Performance
Vijay K Iyengar Ownership Network
Ownership Network List of Vijay K Iyengar
Ownership Network Relation of Vijay K Iyengar
Vijay K Iyengar Owned Company Details
What does Incyte Corp do?
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Who are the key executives at Incyte Corp?
Vijay K Iyengar is the EVP GPS & BD & & Licensing of Incyte Corp. Other key executives at Incyte Corp include Principal Accounting Officer Thomas Tray , EVP & Head of Tech. Operations Michael James Morrissey , and EVP & General Manager & Europe Jonathan Elliott Dickinson .
Incyte Corp (INCY) Insider Trades Summary
Over the past 18 months, Vijay K Iyengar made 3 insider transaction in Incyte Corp (INCY) with a net sale of 30,111. Other recent insider transactions involving Incyte Corp (INCY) include a net purchase of 2,510,403 shares made by Baker Bros. Advisors Lp , a net sale of 46,866 shares made by Barry P Flannelly , and a net sale of 2,787 shares made by Thomas Tray .
In summary, during the past 3 months, insiders sold 0 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 208,851 shares of Incyte Corp (INCY) were sold and 2,510,403 shares were bought by its insiders, resulting in a net purchase of 2,301,552 shares.
Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Incyte Corp Insider Transactions
Vijay K Iyengar Mailing Address
Above is the net worth, insider trading, and ownership report for Vijay K Iyengar. You might contact Vijay K Iyengar via mailing address: 1801 Augustine Cut-off, Wilmington De 19803.